Provider and Caregiver Connection™️: Addressing Patient Concerns During the Treatment of cSCC With Immunotherapy

Release Date: November 27, 2019
Expiration Date: November 27, 2020
Media: Internet - based

Activity Overview

As new agents are available for the treatment of advanced and metastatic cutaneous squamous cell carcinoma (cSCC), there is a need to educate practitioners on the incorporation of recently approved agents into practice based on clinical data. Management of these patients is multidisciplinary and, therefore, possible application of immunotherapeutic approaches must be part of the discussion amongst multidisciplinary colleagues to optimally plan multimodal treatment regimens.

Practitioners who manage cSCC must be knowledgeable in recent strategies for treatment of cSCC, including immunotherapy. Practitioners must also be aware of new treatment-related toxicities associated with immunotherapy and take measures for clear communication with the patient and the caregiver(s) about treatment goals and preemptive management of possible adverse events.

To help you meet this challenge, this Provider and Caregiver Connection™ presents a series of audio interviews with Omid Hamid, MD, an expert in cSCC, who will discuss the current standards of care for advanced and metastatic disease, the recent integration of immunotherapy into the treatment paradigm for cSCC, and the multidisciplinary approach to treatment of cSCC. In addition, Nikhil Khushalani, MD, an expert in cutaneous malignancies, discusses the patient and caregiver experience with George Ebanks, BSN, RN,OCN, an experienced oncology nurse; his patient and survivor of locally advanced cSCC, Tim Nugent; and Tim’s wife and caregiver, Cathy Rowe. This discussion provides insight into the patient and caregiver journey from initial diagnosis through treatment that involved immunotherapy.

Benefits of Participating

• Use the expertise of leading experts in cutaneous malignancies on the diagnosis and current treatment landscape for advanced and metastatic cSCC
• Familiarize yourself with the indicated use of immunotherapy for advanced and metastatic cSCC
• Implement treatment regimens that include recent clinical developments for advanced and metastatic cSCC such as immunotherapy
• Gain perspective from the patient and caregiver point of view to better guide patients with advanced and metastatic cSCC through the diagnostic and treatment process
• Incorporate multidisciplinary discussions further in the treatment planning process for optimal multimodal patient care for cSCC

Acknowledgement of Commercial Support

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.

Target Audience

This educational activity is directed toward medical oncologists, surgical oncologists, specialty surgeons, oncology pathologists, clinical/biomedical investigators, nurse practitioners, physicians’ assistants, nurses and other healthcare professionals interested in the treatment of cSCC. This activity will provide education to a broad multidisciplinary team whom will be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Discuss unmet needs related to treatment of advanced/metastatic cSCC and review emerging treatment paradigms.
• Review recent evidence regarding the use of immunotherapeutic strategies and its impact in the context of changing cSCC care paradigms.
• Utilize multidisciplinary approaches to plan for and proactively mitigate the impact of immune related adverse events (irAEs) in patients with advanced/metastatic cSCC.
• Identify and address patient concerns in the treatment of advanced/metastatic cSCC.

Faculty, Staff, and Planners’ Disclosures

Faculty

Nikhil Khushalani, MD
Vice Chair and Senior Member,
Department of Cutaneous Oncology
Chief of Medical Oncology Service
Moffitt Cancer Center
Tampa, FL

Disclosures: Grant Research Support: Bristol-Myers Squibb, Merck, GlaxoSmithKline, Novartis, Celgene, Huya, Regeneron; Consultant: Bristol-Myers Squibb, Merck, Regeneron, Sanofi, Merck Serono, Array, Huya; Stock/Shareholder: Mazor Robotics, Bellicum Pharmaceuticals Inc., Transenterix Inc., Amarin Corporation plc., Other: AstraZeneca: Data Safety Monitoring Board, Incyte.

Omid Hamid, MD
Chief of Research/Immuno-Oncology
Co-Director, Cutaneous Malignancy Program
The Angeles Clinic and Research Institute
Los Angeles, CA

Disclosures: Grant Research Support: Arcus Biosciences, Aduro Biotech, Akeso Biopharma, Amgen, Array BioPharma, Bristol-Myers Squibb, CytomX, Exelixis, Genentech, GlaxoSmithKline, Immunocore, Incyte Corporation, Iovance Biotherapeutics, Merck, Moderna, Merck-Serono, NextCure, Novartis, Regeneron/Sanofi, Roche, Seattle Genetics, Torque, Zelluna Immunotherapy; Consulting Advisory Boards: Aduro Biotech, Akeso Biopharma Amgen, Array BioPharma, BeiGene, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Immunocore, Incyte Corporation, Janssen, Merck, NextCure, Novartis, Regeneron, Roche, Sanofi, Seattle Genetics, Tempus, Zelluna Immunotherapy; Speakers Bureau: Array BioPharma, Bristol-Myers Squibb, Novartis, Sanofi/Regeneron.

George Ebanks, BSN, RN, OCN
Moffitt Cancer Center
Tampa, FL

Disclosures: no relevant financial relationships with commercial interests.

Disclosures: no relevant financial relationships with commercial interests.

Disclosures: no relevant financial relationships with commercial interests.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER^® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER^® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER^® is required by ACCME to resolve all COI. PER^® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician and nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or the company that provided commercial support.